Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease

Trial Profile

A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DM 199 (Primary)
  • Indications Renal failure
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms REDUX
  • Sponsors DiaMedica Therapeutics
  • Most Recent Events

    • 07 Nov 2019 Status changed from not yet recruiting to recruiting.
    • 14 Oct 2019 According to a DiaMedica Therapeutics media release, the U.S. Food and Drug Administration (FDA) has accepted this trial protocol for the treatment of Chronic Kidney Disease (CKD).The company intends to initiate participant enrollment in the next few weeks.
    • 09 Oct 2019 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top